CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: IFT22 (ImmuneEditome ID:64792)

1. Gene summary of enriched editing regions for IFT22

check button Gene summary
Gene informationGene symbol

IFT22

Gene ID

64792

GeneSynonymsCFAP9|FAP9|RABL5
GeneCytomap

7q22.1

GeneTypeprotein-coding
GeneDescriptionintraflagellar transport protein 22 homolog|RAB, member RAS oncogene family-like 5|RAB, member of RAS oncogene family-like 5|intraflagellar transport 22 homolog|rab-like protein 5
GeneModificationdate20230329
UniprotIDQ9H7X7;F8WDY0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr7:101313422-101314619:-ENST00000422177.4ENSG00000128581.14IFT22splicingTigger17c,MADE1,AluSg,AluSz6,AluScchr7:101313422-101314619:-.alignment
chr7:101318339-101318850:-ENST00000440362.4ENSG00000128581.14IFT22ncRNA_exonicAluJo,AluSzchr7:101318339-101318850:-.alignment


Top

2. Tumor-specific enriched editing regions for IFT22


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr7:101313422-101314619:-BRCAEER3.4763e-06image
ENSG00000128581.14,IFT22BRCAEAG3.5904e-06image
chr7:101313422-101314619:-KIRCEER2.8431e-07image
ENSG00000128581.14,IFT22KIRCEAG2.7978e-07image
chr7:101313422-101314619:-KIRPEER4.2303e-02image
chr7:101313422-101314619:-THCAEER1.8101e-02image
ENSG00000128581.14,IFT22THCAEAG1.8101e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000128581.14,IFT22CHOLPathEAG1.2815e-025.4479e-030.5970image
ENSG00000128581.14,IFT22COADPathEAG7.9512e-043.6125e-030.4923image
ENSG00000128581.14,IFT22ESCACliEAG1.0907e-033.4936e-03-0.4264image
chr7:101313422-101314619:-ESCACliEER1.0907e-033.4936e-03-0.4264image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr7:101313422-101314619:-LUSCEER6.3261e-032.9090e-027.3467e+00image
ENSG00000128581.14,IFT22LUSCEAG2.0582e-032.3916e-027.8206e+00image

Top

3. Enriched editing regions and immune related genes for IFT22


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr7:101313422-101314619:-THCAEERENSG00000068383,INPP5A-0.35512.7937e-113.9303e-17-0.4063imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr7:101313422-101314619:-KIRPEERENSG00000231711,LINC00899-0.44301.0051e-099.4173e-11-0.4250imageNNNAMast_cells_restingGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr7:101313422-101314619:-KIRPEERENSG00000271976,RP11-884K10.7-0.43618.1346e-091.7604e-11-0.4397imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr7:101313422-101314619:-KIRPEERENSG00000200253,RNU6-529P-0.43401.2445e-081.4183e-10-0.4213imageNNNAMast_cells_restingGSVA_HALLMARK_MTORC1_SIGNALING
chr7:101313422-101314619:-KIRPEERENSG00000257122,RRN3P3-0.43671.5483e-081.0271e-09-0.4028imageNNNANK_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr7:101313422-101314619:-KIRPEERENSG00000100106,TRIOBP-0.41113.4469e-088.8194e-10-0.4043imageNNNAMacrophages_M1GSVA_HALLMARK_MTORC1_SIGNALING
chr7:101313422-101314619:-KIRPEERENSG00000229180,GS1-124K5.11-0.41783.5463e-084.8740e-10-0.4099imageNNNAMast_cells_restingGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr7:101313422-101314619:-KIRPEERENSG00000269044,CTC-429P9.3-0.41066.6410e-082.2593e-10-0.4171imageNNNAMacrophages_M1GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr7:101313422-101314619:-KIRPEERENSG00000106479,ZNF862-0.40381.0123e-077.5031e-10-0.4058imageNNNAMacrophages_M1GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr7:101313422-101314619:-KIRPEERENSG00000131591,C1orf159-0.41601.1196e-076.1753e-10-0.4077imageNNNAMacrophages_M1GSVA_HALLMARK_PANCREAS_BETA_CELLS

More results



Top

4. Enriched editing regions and immune related splicing for IFT22


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr7:101313422-101314619:-
ESCAEERIRENSG00000153406.9chr164461679:4461959:4463419:4463512-0.39368.5156e-031.0817e-07-0.4472imageNNNAMast_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000128581.14,IFT22
ESCAEAGIRENSG00000153406.9chr164461679:4461959:4463419:4463512-0.39369.9676e-031.0817e-07-0.4472imageNACIN1;DDX3X;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28B;NOP56;NOP58;PRPF8;PTBP1;RANGAP1;RBFOX2;SF3B4;SND1;SRSF1;TARDBP;U2AF2;UPF1NAMast_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr7:101313422-101314619:-
GBMEERIRENSG00000090060.13chr1496532510:96534563:96535878:965359990.30374.2914e-023.0767e-070.4009imageNNNANK_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr7:101313422-101314619:-
GBMEERIRENSG00000198563.9chr631540321:31540534:31541633:31541729-0.37941.5572e-034.0207e-09-0.4573imageNNDDX39BMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000128581.14,IFT22
GBMEAGMEXENSG00000159063.8chr1178104355:78104453:78106806:78106912:78127357:78127436:78139493:781395920.36466.1978e-032.6674e-070.4029imageNACIN1;ADAR;AIFM1;CNBP;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28B;MOV10;NOP56;NOP58;PRPF8;PTBP1;RANGAP1;RBFOX2;SF3B4;SND1;SRSF1;TARDBP;U2AF2;UPF1NAT_cells_gamma_deltaGSVA_HALLMARK_MITOTIC_SPINDLE
chr7:101313422-101314619:-
GBMEERMEXENSG00000159063.8chr1178104355:78104453:78106806:78106912:78127357:78127436:78139493:781395920.36684.9044e-032.4969e-070.4038imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_MITOTIC_SPINDLE
chr7:101313422-101314619:-
GBMEERMEXENSG00000159063.8chr1178104355:78104453:78106806:78106946:78127357:78127436:78139493:781395920.36575.1259e-032.5589e-070.4034imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000128581.14,IFT22
GBMEAGMEXENSG00000159063.8chr1178104355:78104453:78106806:78106946:78127357:78127436:78139493:781395920.36366.4892e-032.7288e-070.4026imageNACIN1;ADAR;AIFM1;CNBP;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28B;MOV10;NOP56;NOP58;PRPF8;PTBP1;RANGAP1;RBFOX2;SF3B4;SND1;SRSF1;TARDBP;U2AF2;UPF1NAT_cells_gamma_deltaGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000128581.14,IFT22
GBMEAGIRENSG00000090060.13chr1496532510:96534563:96535878:965359990.30564.6797e-022.9682e-070.4014imageNACIN1;ADAR;AIFM1;CNBP;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28B;MOV10;NOP56;NOP58;PRPF8;PTBP1;RANGAP1;RBFOX2;RTCB;SF3B4;SND1;SRSF1;TARDBP;U2AF2;UPF1NANK_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000128581.14,IFT22
GBMEAGIRENSG00000198563.9chr631540321:31540534:31541633:31541729-0.37492.1921e-037.2037e-09-0.4506imageNACIN1;ADAR;AIFM1;DDX3X;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LIN28;LIN28B;MOV10;NOP56;NOP58;PRPF8;PTBP1;RANGAP1;RBFOX2;SF3B4;SND1;SRSF1;TARDBP;U2AF2;UPF1DDX39BMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

More results



Top

5. Enriched editing regions and immune infiltration for IFT22


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr7:101313422-101314619:-BRCAEERMacrophages_M11.8220e-040.1283image
ENSG00000128581.14,IFT22BRCAEAGMacrophages_M12.0570e-040.1273image
ENSG00000128581.14,IFT22CESCEAGT_cells_CD4_memory_activated1.1130e-030.3791image
ENSG00000128581.14,IFT22COADEAGMacrophages_M21.5253e-020.4389image
chr7:101313422-101314619:-ESCAEERT_cells_regulatory_(Tregs)1.3776e-02-0.2131image
ENSG00000128581.14,IFT22ESCAEAGT_cells_regulatory_(Tregs)1.3776e-02-0.2131image
chr7:101313422-101314619:-GBMEEREosinophils5.2926e-030.2251image
ENSG00000128581.14,IFT22GBMEAGEosinophils5.4973e-030.2242image
chr7:101313422-101314619:-HNSCEERNeutrophils1.5886e-020.2594image
ENSG00000128581.14,IFT22HNSCEAGNeutrophils1.5891e-020.2594image
chr7:101313422-101314619:-KIRCEERMonocytes2.8141e-03-0.1811image
ENSG00000128581.14,IFT22KIRCEAGMonocytes2.7983e-03-0.1812image
chr7:101313422-101314619:-KIRPEERT_cells_CD4_memory_resting6.3627e-03-0.1864image
ENSG00000128581.14,IFT22KIRPEAGT_cells_CD4_memory_resting6.6635e-03-0.1849image
chr7:101313422-101314619:-LGGEERMacrophages_M02.6537e-03-0.1461image
ENSG00000128581.14,IFT22LGGEAGMacrophages_M02.9044e-03-0.1448image
chr7:101313422-101314619:-LUADEERT_cells_CD82.7718e-020.1946image
ENSG00000128581.14,IFT22LUADEAGT_cells_CD82.7718e-020.1946image
chr7:101313422-101314619:-OVEERT_cells_CD82.8568e-040.2179image
ENSG00000128581.14,IFT22OVEAGT_cells_CD82.7277e-040.2186image
ENSG00000128581.14,IFT22PAADEAGT_cells_follicular_helper1.3293e-020.3206image
chr7:101313422-101314619:-PCPGEEREosinophils1.3967e-030.4573image
ENSG00000128581.14,IFT22PCPGEAGEosinophils1.3967e-030.4573image
chr7:101313422-101314619:-PRADEERMast_cells_resting8.6764e-03-0.1354image
ENSG00000128581.14,IFT22PRADEAGMast_cells_resting1.9271e-02-0.1207image
chr7:101313422-101314619:-SARCEERT_cells_CD4_memory_activated3.0541e-030.2851image
ENSG00000128581.14,IFT22SARCEAGT_cells_CD4_memory_activated2.9954e-030.2856image
ENSG00000128581.14,IFT22SKCMEAGDendritic_cells_resting3.7761e-020.1957image
chr7:101313422-101314619:-STADEERT_cells_CD4_memory_activated1.9521e-020.1504image
ENSG00000128581.14,IFT22STADEAGT_cells_CD4_memory_activated1.9439e-020.1505image
ENSG00000128581.14,IFT22TGCTEAGMacrophages_M26.7454e-06-0.4617image
chr7:101313422-101314619:-THCAEERT_cells_regulatory_(Tregs)3.0499e-040.1808image
ENSG00000128581.14,IFT22THCAEAGT_cells_regulatory_(Tregs)3.0499e-040.1808image
ENSG00000128581.14,IFT22UCECEAGDendritic_cells_activated2.2169e-020.2170image
ENSG00000128581.14,IFT22UCSEAGNK_cells_resting2.2200e-02-0.4030image
ENSG00000128581.14,IFT22UVMEAGT_cells_CD4_naive4.4168e-02-0.3328image


Top

6. Enriched editing regions and immune gene sets for IFT22


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr7:101313422-101314619:-THCAEER1.4559e-02image9.4252e-040.1658image
ENSG00000128581.14,IFT22THCAEAG1.4559e-02image9.4252e-040.1658image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr7:101313422-101314619:-PRADEER9.2402e-030.13433.3847e-020.10961.0105e-030.16912.5268e-040.1879image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr7:101313422-101314619:-ACCGSVA_HALLMARK_DNA_REPAIREER3.1742e-03-0.5129image
ENSG00000128581.14,IFT22ACCGSVA_HALLMARK_DNA_REPAIREAG3.1742e-03-0.5129image
ENSG00000128581.14,IFT22BLCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.1426e-020.2378image
chr7:101313422-101314619:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.6009e-230.3342image
ENSG00000128581.14,IFT22BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7545e-230.3339image
ENSG00000128581.14,IFT22CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.3980e-040.4228image
ENSG00000128581.14,IFT22CHOLGSVA_HALLMARK_APOPTOSISEAG6.2755e-03-0.5891image
ENSG00000128581.14,IFT22COADGSVA_HALLMARK_COAGULATIONEAG4.0657e-020.3759image
ENSG00000128581.14,IFT22ESCAGSVA_HALLMARK_G2M_CHECKPOINTEAG2.2257e-02-0.1981image
chr7:101313422-101314619:-ESCAGSVA_HALLMARK_G2M_CHECKPOINTEER2.2257e-02-0.1981image
chr7:101313422-101314619:-GBMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.2480e-05-0.3365image
ENSG00000128581.14,IFT22GBMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.0875e-05-0.3311image
ENSG00000128581.14,IFT22HNSCGSVA_HALLMARK_COAGULATIONEAG2.4353e-050.4383image
chr7:101313422-101314619:-HNSCGSVA_HALLMARK_COAGULATIONEER2.4663e-050.4380image
ENSG00000128581.14,IFT22KIRCGSVA_HALLMARK_APICAL_SURFACEEAG1.8475e-03-0.1887image
chr7:101313422-101314619:-KIRCGSVA_HALLMARK_APICAL_SURFACEEER1.8786e-03-0.1884image
ENSG00000128581.14,IFT22KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.8665e-080.3727image
chr7:101313422-101314619:-KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.5326e-080.3756image
chr7:101313422-101314619:-LGGGSVA_HALLMARK_UV_RESPONSE_DNEER3.9292e-03-0.1403image
ENSG00000128581.14,IFT22LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG3.9401e-03-0.1402image
ENSG00000128581.14,IFT22LIHCGSVA_HALLMARK_HYPOXIAEAG3.1867e-030.5766image
chr7:101313422-101314619:-LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7547e-020.2096image
ENSG00000128581.14,IFT22LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7547e-020.2096image
chr7:101313422-101314619:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5613e-050.3116image
ENSG00000128581.14,IFT22LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.1079e-050.3085image
ENSG00000128581.14,IFT22MESOGSVA_HALLMARK_P53_PATHWAYEAG2.7594e-040.5278image
chr7:101313422-101314619:-MESOGSVA_HALLMARK_P53_PATHWAYEER2.7594e-040.5278image
chr7:101313422-101314619:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2303e-090.3519image
ENSG00000128581.14,IFT22OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.0985e-090.3524image
ENSG00000128581.14,IFT22PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.4203e-02-0.3177image
chr7:101313422-101314619:-PCPGGSVA_HALLMARK_UV_RESPONSE_UPEER1.3153e-050.5946image
ENSG00000128581.14,IFT22PCPGGSVA_HALLMARK_UV_RESPONSE_UPEAG1.3153e-050.5946image
chr7:101313422-101314619:-PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.2004e-090.2932image
ENSG00000128581.14,IFT22PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.3826e-070.2520image
ENSG00000128581.14,IFT22SARCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.8776e-03-0.2986image
chr7:101313422-101314619:-SARCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.8501e-03-0.2990image
ENSG00000128581.14,IFT22SKCMGSVA_HALLMARK_HEME_METABOLISMEAG2.6430e-040.3368image
chr7:101313422-101314619:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.3046e-040.2161image
ENSG00000128581.14,IFT22STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.5542e-040.2156image
ENSG00000128581.14,IFT22TGCTGSVA_HALLMARK_GLYCOLYSISEAG3.7902e-05-0.4266image
chr7:101313422-101314619:-THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER2.4372e-070.2562image
ENSG00000128581.14,IFT22THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG2.4372e-070.2562image
ENSG00000128581.14,IFT22THYMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.3943e-030.3390image
ENSG00000128581.14,IFT22UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1184e-040.3447image
ENSG00000128581.14,IFT22UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.9018e-030.5094image
ENSG00000128581.14,IFT22UVMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.7262e-030.4651image


Top

7. Enriched editing regions and drugs for IFT22


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr7:101313422-101314619:-ACCGW843682XEER1.9415e-030.5347image
ENSG00000128581.14,IFT22ACCGW843682XEAG1.9415e-030.5347image
ENSG00000128581.14,IFT22BLCAAxitinibEAG8.8490e-050.4192image
chr7:101313422-101314619:-BRCACGP.082996EER1.6201e-06-0.1640image
ENSG00000128581.14,IFT22BRCACGP.082996EAG1.4885e-06-0.1646image
ENSG00000128581.14,IFT22CESCGW843682XEAG7.2953e-03-0.3158image
ENSG00000128581.14,IFT22CHOLIPA.3EAG2.0771e-02-0.5128image
ENSG00000128581.14,IFT22ESCAEHT.1864EAG9.8421e-050.3312image
chr7:101313422-101314619:-ESCAEHT.1864EER9.8421e-050.3312image
ENSG00000128581.14,IFT22GBMGefitinibEAG4.2697e-04-0.2822image
chr7:101313422-101314619:-GBMGefitinibEER3.0613e-04-0.2889image
ENSG00000128581.14,IFT22HNSCEmbelinEAG3.3305e-04-0.3780image
chr7:101313422-101314619:-HNSCEmbelinEER3.3693e-04-0.3777image
ENSG00000128581.14,IFT22KIRCMethotrexateEAG7.9973e-07-0.2950image
chr7:101313422-101314619:-KIRCMethotrexateEER7.6204e-07-0.2956image
chr7:101313422-101314619:-KIRPCCT018159EER3.7909e-070.3396image
ENSG00000128581.14,IFT22KIRPCCT018159EAG3.8023e-070.3388image
ENSG00000128581.14,IFT22LGGLenalidomideEAG2.4271e-030.1474image
chr7:101313422-101314619:-LGGLenalidomideEER1.9217e-030.1508image
ENSG00000128581.14,IFT22LIHCBIRB.0796EAG8.8918e-04-0.6335image
chr7:101313422-101314619:-LUADEHT.1864EER1.1863e-020.2218image
ENSG00000128581.14,IFT22LUADEHT.1864EAG1.1863e-020.2218image
chr7:101313422-101314619:-LUSCAZD6244EER2.1455e-03-0.2299image
ENSG00000128581.14,IFT22LUSCAZD6244EAG2.4303e-03-0.2272image
ENSG00000128581.14,IFT22MESOGW843682XEAG1.1548e-02-0.3817image
chr7:101313422-101314619:-MESOGW843682XEER1.1548e-02-0.3817image
chr7:101313422-101314619:-OVFTI.277EER6.8119e-070.2952image
ENSG00000128581.14,IFT22OVFTI.277EAG4.9686e-070.2987image
chr7:101313422-101314619:-PCPGMethotrexateEER1.1025e-02-0.3715image
ENSG00000128581.14,IFT22PCPGMethotrexateEAG1.1025e-02-0.3715image
chr7:101313422-101314619:-PRADJNK.Inhibitor.VIIIEER7.7783e-05-0.2026image
ENSG00000128581.14,IFT22PRADJNK.Inhibitor.VIIIEAG1.7598e-04-0.1923image
ENSG00000128581.14,IFT22SARCAG.014699EAG4.7193e-030.2725image
chr7:101313422-101314619:-SARCAG.014699EER5.2859e-030.2691image
ENSG00000128581.14,IFT22SKCMJNK.9LEAG8.2529e-03-0.2474image
chr7:101313422-101314619:-STADCisplatinEER3.0723e-03-0.1899image
ENSG00000128581.14,IFT22STADCisplatinEAG3.1209e-03-0.1896image
ENSG00000128581.14,IFT22TGCTDocetaxelEAG4.0409e-050.4252image
chr7:101313422-101314619:-THCACI.1040EER5.0869e-11-0.3226image
ENSG00000128581.14,IFT22THCACI.1040EAG5.0869e-11-0.3226image
ENSG00000128581.14,IFT22THYMEtoposideEAG5.6466e-040.3817image
ENSG00000128581.14,IFT22UCECJNK.Inhibitor.VIIIEAG8.2404e-05-0.3649image
ENSG00000128581.14,IFT22UCSDasatinibEAG6.1022e-05-0.6479image
ENSG00000128581.14,IFT22UVMBortezomibEAG2.5576e-04-0.5667image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType